Role of the PPAR-α agonist fenofibrate in severe pediatric burn

Itoro E. Elijah, Elisabet Børsheim, Dirk M. Maybauer, Celeste Finnerty, David Herndon, Marc O. Maybauer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric, and renal cells, which allow it to provide systemic regulation of lipoprotein metabolism, fatty acid oxidation, and fatty acid transport. Hyperglycemia is a common complication found in the burn population because hepatic glucose production and catecholamine-mediated hepatic glycogenolysis are augmented. Insulin resistance occurs often in these patients and is associated with poor outcomes. In the pediatric burn population, fenofibrate has been found to ameliorate or decrease the number of hypoglycemic episodes when compared to management with insulin alone. Its mechanism of action is thought to involve an improvement in insulin signaling in skeletal muscle, as well as improvements in mitochondrial function, glucose oxidation, and insulin sensitivity. The long term use of fenofibrate in severely burned patients may improve hyperglycemia and insulin resistance, as well as improve wound healing, and reduce apoptosis, and oxidative stress.

Original languageEnglish (US)
Pages (from-to)481-486
Number of pages6
JournalBurns
Volume38
Issue number4
DOIs
StatePublished - Jun 2012

Fingerprint

Fenofibrate
Peroxisome Proliferator-Activated Receptors
Insulin Resistance
Pediatrics
Hyperglycemia
Liver
Skeletal Muscle
Fatty Acids
Insulin
Glycogenolysis
Glucose
PPAR alpha
Dyslipidemias
Hypoglycemic Agents
Wound Healing
Population
Lipoproteins
Catecholamines
Oxidative Stress
Anti-Inflammatory Agents

Keywords

  • Burns
  • Fenofibrate
  • Hypermetabolism
  • Insulin
  • Lipolysis
  • PPAR

ASJC Scopus subject areas

  • Emergency Medicine
  • Critical Care and Intensive Care Medicine
  • Surgery

Cite this

Elijah, I. E., Børsheim, E., Maybauer, D. M., Finnerty, C., Herndon, D., & Maybauer, M. O. (2012). Role of the PPAR-α agonist fenofibrate in severe pediatric burn. Burns, 38(4), 481-486. https://doi.org/10.1016/j.burns.2011.12.004

Role of the PPAR-α agonist fenofibrate in severe pediatric burn. / Elijah, Itoro E.; Børsheim, Elisabet; Maybauer, Dirk M.; Finnerty, Celeste; Herndon, David; Maybauer, Marc O.

In: Burns, Vol. 38, No. 4, 06.2012, p. 481-486.

Research output: Contribution to journalArticle

Elijah, IE, Børsheim, E, Maybauer, DM, Finnerty, C, Herndon, D & Maybauer, MO 2012, 'Role of the PPAR-α agonist fenofibrate in severe pediatric burn', Burns, vol. 38, no. 4, pp. 481-486. https://doi.org/10.1016/j.burns.2011.12.004
Elijah IE, Børsheim E, Maybauer DM, Finnerty C, Herndon D, Maybauer MO. Role of the PPAR-α agonist fenofibrate in severe pediatric burn. Burns. 2012 Jun;38(4):481-486. https://doi.org/10.1016/j.burns.2011.12.004
Elijah, Itoro E. ; Børsheim, Elisabet ; Maybauer, Dirk M. ; Finnerty, Celeste ; Herndon, David ; Maybauer, Marc O. / Role of the PPAR-α agonist fenofibrate in severe pediatric burn. In: Burns. 2012 ; Vol. 38, No. 4. pp. 481-486.
@article{a4dbf99ec6004499a07de7f2a8b21c60,
title = "Role of the PPAR-α agonist fenofibrate in severe pediatric burn",
abstract = "Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric, and renal cells, which allow it to provide systemic regulation of lipoprotein metabolism, fatty acid oxidation, and fatty acid transport. Hyperglycemia is a common complication found in the burn population because hepatic glucose production and catecholamine-mediated hepatic glycogenolysis are augmented. Insulin resistance occurs often in these patients and is associated with poor outcomes. In the pediatric burn population, fenofibrate has been found to ameliorate or decrease the number of hypoglycemic episodes when compared to management with insulin alone. Its mechanism of action is thought to involve an improvement in insulin signaling in skeletal muscle, as well as improvements in mitochondrial function, glucose oxidation, and insulin sensitivity. The long term use of fenofibrate in severely burned patients may improve hyperglycemia and insulin resistance, as well as improve wound healing, and reduce apoptosis, and oxidative stress.",
keywords = "Burns, Fenofibrate, Hypermetabolism, Insulin, Lipolysis, PPAR",
author = "Elijah, {Itoro E.} and Elisabet B{\o}rsheim and Maybauer, {Dirk M.} and Celeste Finnerty and David Herndon and Maybauer, {Marc O.}",
year = "2012",
month = "6",
doi = "10.1016/j.burns.2011.12.004",
language = "English (US)",
volume = "38",
pages = "481--486",
journal = "Burns",
issn = "0305-4179",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Role of the PPAR-α agonist fenofibrate in severe pediatric burn

AU - Elijah, Itoro E.

AU - Børsheim, Elisabet

AU - Maybauer, Dirk M.

AU - Finnerty, Celeste

AU - Herndon, David

AU - Maybauer, Marc O.

PY - 2012/6

Y1 - 2012/6

N2 - Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric, and renal cells, which allow it to provide systemic regulation of lipoprotein metabolism, fatty acid oxidation, and fatty acid transport. Hyperglycemia is a common complication found in the burn population because hepatic glucose production and catecholamine-mediated hepatic glycogenolysis are augmented. Insulin resistance occurs often in these patients and is associated with poor outcomes. In the pediatric burn population, fenofibrate has been found to ameliorate or decrease the number of hypoglycemic episodes when compared to management with insulin alone. Its mechanism of action is thought to involve an improvement in insulin signaling in skeletal muscle, as well as improvements in mitochondrial function, glucose oxidation, and insulin sensitivity. The long term use of fenofibrate in severely burned patients may improve hyperglycemia and insulin resistance, as well as improve wound healing, and reduce apoptosis, and oxidative stress.

AB - Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric, and renal cells, which allow it to provide systemic regulation of lipoprotein metabolism, fatty acid oxidation, and fatty acid transport. Hyperglycemia is a common complication found in the burn population because hepatic glucose production and catecholamine-mediated hepatic glycogenolysis are augmented. Insulin resistance occurs often in these patients and is associated with poor outcomes. In the pediatric burn population, fenofibrate has been found to ameliorate or decrease the number of hypoglycemic episodes when compared to management with insulin alone. Its mechanism of action is thought to involve an improvement in insulin signaling in skeletal muscle, as well as improvements in mitochondrial function, glucose oxidation, and insulin sensitivity. The long term use of fenofibrate in severely burned patients may improve hyperglycemia and insulin resistance, as well as improve wound healing, and reduce apoptosis, and oxidative stress.

KW - Burns

KW - Fenofibrate

KW - Hypermetabolism

KW - Insulin

KW - Lipolysis

KW - PPAR

UR - http://www.scopus.com/inward/record.url?scp=84859801219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859801219&partnerID=8YFLogxK

U2 - 10.1016/j.burns.2011.12.004

DO - 10.1016/j.burns.2011.12.004

M3 - Article

VL - 38

SP - 481

EP - 486

JO - Burns

JF - Burns

SN - 0305-4179

IS - 4

ER -